Advertisement


Bruce Minsky, MD, on Clinical Trial Results: The ASCENDE-RT Trial and a Multicenter Study on Prostate Cancer

2015 ASTRO Annual Meeting

Advertisement

Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).



Related Videos

Breast Cancer

Vratislav Strnad, MD, PhD, on Multicatheter Brachytherapy After Breast-Conserving Surgery

Vratislav Strnad, MD, PhD, of the University Hospital in Erlangen, discusses results from a European study comparing accelerated partial-breast irradiation using brachytherapy, to the standard treatment of whole-breast irradiation for women with low-risk breast cancer (Abstract LBA7).

Symptom Management
Palliative Care
Pain Management

Samuel Chao, MD, on Improving the Consistency of Radiation Oncology Processes

Samuel Chao, MD, of Cleveland Clinic, discusses the QMAP program and data-driven management, which offer ways to improve consistency and drive quality in radiation oncology departments (Abstract 39).

CNS Cancers
Gastroesophageal Cancer

Anita Mahajan, MD, on Radiotherapy Advances in the CNS and Aerodigestive Tract

Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).

Lung Cancer

Roy Decker, MD, PhD, on Chemoradiation in Elderly Patients With Limited-Stage SCLC

Roy Decker, MD, PhD, of Yale University School of Medicine, discusses a National Cancer Database analysis that showed elderly patients with limited-stage small cell lung cancer can benefit from adding concurrent radiation to chemotherapy (Abstract 1010).

Prostate Cancer

James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer

James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).

Advertisement

Advertisement




Advertisement